Cognitive Assessments and Biohaven

Selected news for the healthcare topic - Cognitive Assessments, and the company - Biohaven. We have 5 shared news items for this connection to-date.

Please provide a valid email address.
Cognitive Assessments Shares Healthcare News With (link):
Healthcare Topics
Companies

Selected Headlines

Date Headline (link) Source Relevant Snippet
11/5/2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole – Company Announcement - FT.com Financial Times NEW HAVEN, Conn. , Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd . (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI ...
11/5/2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole PR Newswire NEW HAVEN, Conn. - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI) is expected before the ...
11/5/2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole | BioSpace Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole Published: Nov 05, 2019 NEW HAVEN, Conn. , Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharma Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical ... troriluzole in Alzheimer's disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI) is expected before the end of 2019. "We are hopeful this study will demonstrate that troriluzole can ...
11/5/2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer’s Disease Clinical Trial Of Troriluzole – Connecticut Hispano News Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer’s Disease Clinical Trial Of Troriluzole noviembre 5, 2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer’s Disease Clinical Trial Of Troriluzole 2019-11-05T07:30: NEW HAVEN, Conn. , Nov. 5 ... troriluzole in Alzheimer’s disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI) is expected before the end of 2019. «We are hopeful this study will demonstrate that troriluzole can ...
11/5/2019 Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole - GuruFocus.com ... Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI) is expected before the end of 2019 ...